El haloperidol durante dos meses reapareci la corea cual resolvi pidamente reinstaurar tratamiento. Request PDF on ResearchGate Chor de Sydenham chez . Sydenham se graduó de la Universidad de Oxford en y obtuvo el título de del láudano de opio y de la corteza del árbol de chinchona en el tratamiento de logros están el descubrimiento de la Corea de Sydenham, también conocida. eficacia de carbamazepina, haloperidol y acido valproico en el tratamiento de niños con corea de Sydenham: seguimiento clínico de 18 pacientes’ in DOAJ.

Author: Shall Ararg
Country: Saint Lucia
Language: English (Spanish)
Genre: Education
Published (Last): 8 March 2012
Pages: 255
PDF File Size: 15.75 Mb
ePub File Size: 6.39 Mb
ISBN: 810-2-97496-861-5
Downloads: 10226
Price: Free* [*Free Regsitration Required]
Uploader: Mautaxe

HP, a dopamine receptor blocker, has been used to treat SC, although this drug is frequently associated with side effects such as parkinsonism and dystonia More specifically, the World Health Organization recommends 1.

Neuropsychiatric symptoms, including obsessive compulsive behaviors, personality changes, emotional lability, distractibility, irritability, anxiety, dw behaviors, and anorexia, are common and frequently predate the appearance of chorea. Sedatives, dopaminergic receptor antagonists, and other drugs reduce the time of convalescence of the patients that harbor this disorder, with varying degrees of success. The abnormal balance between the dopaminergic and cholinergic systems that determines dopaminergic hyperactivity has been pointed out as the main mechanism underlying SC.

Although there is a theoretical basis for IVIG and plasmapheresis and trratamiento appears to have at least equal efficacy in a single small comparison study, we hesitate to recommend tratameinto approaches before a trial with steroids. Beneficial use of immunoglobulins in the treatment of Sydenham chorea. Other reports describe tetrabenazine failure in a single patient 37 and side effects including quadriparesis and dysarthria that resolved with its withdrawal.

SC is a movement disorder that affects patients aged 5 to 15 years, with a peak incidence at 8 years, and a 2: Only three of the patients that received haloperidol improved. Chlorpromazine may be effective, but detailed information on dosing and efficacy is lacking. Chorea, hemichorea, hemiballismus, choreathetosis and related disorders of movements. The number of patients that responded to treatment at the end of the first week was dr higher in the group that received VPA.


Pimozide 2 mg twice a day was reported successful in a total of five patients. Comparatively, the streptozyme test appears to be more sensible than other bacterial antigens. Other neurologic symptoms in SC can include motor impersistence, hypometric saccades, reduced muscle tone, tics, clumsiness, dysarthria, and weakness. Author information Article notes Copyright and License information Disclaimer. This test defines antibodies to five streptococcal exo-enzymes, including streptolysine-O, and its titers remain elevated for several weeks.


Dev Med Child Neurol ; The authors concluded that steroids significantly decreased chorea intensity and the time to remission, although relapse rates were the same in both groups.

El haloperidol durante dos meses reapareci la corea cual resolvi pidamente reinstaurar tratamiento. The study was authorized to be carried out by the Ethics Committee of cotea University Hospital.

Placebo-controlled trials would be ideal, but are difficult to justify.

Treatment of Sydenham’s Chorea: A Review of the Current Evidence

The increment observed in the former usually appears early during the course of the infection and diminishes rapidly before the clinical signs of chorea develop. American Society for Microbiology, The purpose of the present investigation is to compare and contrast the efficacy of HP, CBZ, and VPA in the treatment of SC in a series of 18 patients through the analysis of clinical and laboratory findings, clinical course, and side effects related to these drugs. Haloperidol and pimozide are described as successful agents in some case series focusing on other aspects of SC and as a failed primary therapy in published reports describing alternative agents.

Table 1 Symptomatic Treatments. Neuroimaging is usually unremarkable A single case report suggested improvement of symptoms in four patients with SC because of the administration of vitamin E 50 IU administered daily for 2 weeks.


Secondary antibiotic prophylaxis has been shown to sydenhamm the risk of new cardiac lesions associated with recurrent rheumatic fever. Five patients receiving carbamazepine showed improvement without side effects.

Treatment of Sydenham’s Chorea: A Review of the Current Evidence

These reappearances of chorea were not predictable by either prior rheumatic fever activity or cardiac findings. In addition, studies vary on when and how clinical assessments were performed, whether treatment was primary or secondary, and how long symptoms had been present before treatment was initiated.

The corea de sydenham fisiopatologia were divided in three equal groups, and were given a standardized dose of each of the drugs built-up over a week. Classically, chorea in SC is generalized; however, hemi-chorea trqtamiento in about one-quarter of patients.


The remaining case failed to improve. In addition, the time to improvement was significantly shorter in this group as compared to both the HP and CBZ groups. Our members Our publisher members Our sponsors Our volunteers.

One prospective study of 32 patients with SC, followed for more than 2. In summary 18 out of 18 patients appeared to respond to IVIG, including an additional comparison study of IVIG, plasmapheresis and steroids discussed below.

Complete remission was achieved by 54 days in the prednisone group and days in the placebo group. Medications such as valproic acid and carbamazepine, are attractive choices based on their low side effect profile and preliminary suggestive data that they may be as effective as haloperidol. Sydenham’s chorea may be a risk factor for drug induced parkinsonism.